Matsumoto M, Itoh S, Tsunematsu M, Yugawa K, et al. Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer. Surg Today 2026 Jan 5. doi: 10.1007/s00595-025-03227.
PMID: 41491748